Ex vivo zidovudine (AZT) treatment of CD34+ bone marrow progenitors causes decreased steady state mitochondrial DNA (mtDNA) and increased lactate production

Abstract

Haematopoietic suppression is one of the dose-limiting side effects of chronic zidovudine (AZT) therapy. We tested the hypothesis that AZT would reduce mitochondrial DNA (mtDNA) content in haematopoietic progenitors causing impaired haematopoiesis and mitochondrial dysfunction. We studied the effects of AZT 0 ^/ 50 M in vitro, on normal human CD34 / haematopoietic progenitor cells cultured ex vivo for up to 12 days. The mean AZT IC₅₀ for granulocyte (phenotype CD15 / /CD14 /) and erythroid (phenotype glycophorin / /CD45 /) cell proliferation was 2.5 M (SD9 / 0.7) and 0.023 M (SD9 / 0.005), respectively. In myeloid-rich cell cultures, the mean lactate content of the media, compared to untreated controls, increased by 86% (SD9 / 23) at 10 M AZT and in erythroid-rich cultures it increased by 134% (SD9 / 24) in the presence of 0.5 M AZT. In myeloid-rich cultures the AZT IC₅₀ for the reduction in the mitochondrial/nuclear DNA content ratio was 5.6 M, whereas in erythroid rich cultures this AZT IC₅₀ was B ^/ 0.0005 M. AZT produced concentration-dependent inhibition of CD34 / progenitor proliferation into both myeloid and erythroid lineages; erythropoiesis was more sensitive than myelopoiesis. Concurrently, AZT reduced steady state mtDNA content, while increasing lactate production. These findings support the hypothesis that mtDNA is one of the intracellular targets involved in the pathogenesis of AZT-associated bone marrow progenitor cell toxicity.

Keywords

AZT haematopoietic toxicity mitochondrial DNA

References

Mitsuya H , Jarrett RF , Matsukura M , Di Marzo VF , DeVico AL , Sarngadharan MG , et al. Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunode”ciency virus) DNA synthesis and RNA expression in T cells protected by 2’,3’-dideoxynucleosides in vitro . Proc Natl Acad Sci USA 1987; 84: 2033-2037 .

Mitsuya H , Broder S . Strategies for antiviral therapy in AIDS . Nature 1987; 325: 773-778 .

Yarchoan R , Klecker RW , Weinhold KJ , Markham PD , Lyerly HK , Durack DT , et al. Administration of 3’-azido-3’-deoxythymidine, an inhibitor of HTLV-III/ LAV replication, to patients with AIDS or AIDS-related complex . Lancet 1986; 1: 575-580 .

Fischl MA , Richman DD , Hansen N , Collier AC , Carey JT , Para MF , et al. The safety and ef”cacy of zidovu- dine (AZT) in the treatment of subjects with mildly symptomatic human immunode”ciency virus type 1 (HIV-1) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group [see comments] . Ann Int Med 1990; 112: 727-737 .

Fischl MA , Richman DD , Causey DM , Grieco MH , Bryson Y , Mildvan D , et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS- related complex. AZT Collaborative Working Group . JAMA 1989; 262: 2405-2410 .

Richman DD , Fischl MA , Grieco MH , Gottlieb MS , Volberding PA , Laskin OL , et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial . N Engl J Med 1987; 317: 192-197 .

Volberding PA , Lagakos SW , Koch MA , Pettinelli C , Myers MW , Booth DK , et al. Zidovudine in asymptomatic human immunode”ciency virus infection A controlled trial in persons with fewer than 500 CD4- positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases . N Engl J Med 1990; 322: 941-949 .

Dybul M , Fauci AS , Bartlett JG , Kaplan JE , Pau AK and Panel on Clinical Practices for Treatment of HIV-1. Guidelines for using antiretroviral agents among HIV- 1-infected adults and adolescents . Ann Intern Med 2003; 137; 381-433 .

Matheron S , Descamps D , Boue F , Livrozet JM , Lafeuillade A , Aquilina C , et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nel”navir as ”rst-line therapy in HIV-1-infected adults: a randomized trial . Antivir Ther 2003; 8: 163-167 .

10.

Gogu SR , Beckman BS , Agrawal KC . Anti-HIV-1 drugs: comparative toxicities in murine fetal liver and bone marrow erythroid progenitor cells . Life Sci 1989; 45: iii-vii .

11.

Inque T , Tsushita K , Itoh T , Ogura M , Hotta T , Sanayoshi M , et al. In vitro bone marrow toxicity of nucleoside analogs against human immunode”ciency virus . Antimicrob Agents Chemother 1989; 33: 576-579 .

12.

Bhalla K , Birkhofer M , Grant S , Graham G . The effect of recombinant human granulocyte-macrophage colony- stimulating factor (rGM-CSF) on 3’-azido-3’-deoxythymidine (AZT)-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells . Exp Hematol 1989; 17: 17-20 .

13.

Sommadossi JP , Carlisle R . Toxicity of 3’-azido-3’-deoxythymidine and 9-(1,3-dihydroxy-2-propoxy- methyl)guanine for normal human hematopoietic progenitor cells in vitro . Antimicrob Agents Chemother 1987; 31: 452-454 .

14.

Bhalla K , Birkhofer M , Li GR , Grant S , MacLaughlin W , Cole J , et al. 2’-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3’-azido-3’-deoxythymidine with preservation of antiretroviral activity . Blood 1989; 74: 1923-1928 .

15.

Ganser A , Greher J , Volkers B , Staszewski S , Hoelzer D . Inhibitory effect of azidothymidine, 2’-3’-dideoxyadenosine, and 2’-3’-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS . Exp Hematol 1989; 17: 321-325 .

16.

Dournon E , Matheron S , Rozenbaum W , Gharakhanian S , Michon C , Girard PM , et al. Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex . Lancet 1988; 2: 1297-1302 .

17.

Egger M , May M , Chene G , Phillips AN , Ledergerber B , Dabis , et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies . Lancet 2002; 360: 119-129 .

18.

Furman PS , Fyfe JA , St.Clair MH , Weinhold K , Rideout JL , Freeman GA , et al. Phosphorylation of 3’-azido- 3’deoxthymidine and selective interaction of the 5’-triphosphate with human immunode”ciency virus reverse transcriptase . Proc Natl Acad Sci USA 1986; 83: 8333-8337 .

19.

Reardon JE , Miller WH . Human Immunode”ciency Virus Reverse Transcriptase. Substrate and inhibitor kinetics with thymidine 5’-triphosphate and 3’-azido- 3’-deoxythymidine 5’-triphosphate . J Biol Chem 1990; 265: 20302-2307 .

20.

Huang P , Farquhar D , Plunkett W . Selective action of 3’-azido-3’-doexythymidine 5’-triphosphate on viral reverse transcriptase and human DNA polymerases . J Biol Chem. 1990; 265: 11914-11918 .

21.

Parker WH , White EL , Shaddix SC , Ross LJ , Buckheit RW , Germany JM et al. Mechanism of inhibition of human immunode”ciency virus type 1 reverse transcriptase and human DNA polymerases, and gamma by the 5’-triphosphates of carbovir, 3’-azido- 3’-deoxythymidine, 2’,3’-dideoxyguanosine and 3’-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs . J Biol Chem 1991; 266: 1754-1762 .

22.

Cheng YC , Dutschman GE , Bastow KF , Sarngadharan MG , Ting RY . Human immunode”ciency virus reverse transcriptase: general properties and its interactions with nucleoside triphosphate analogs . J Biol Chem 1987; 262: 2187-2189 .

23.

Konig H , Behr E , Lower J , Kurth R . Azidothymidine triphosphate is an inhibitor of both human immunode”ciency virus type 1 reverse transcriptase and DNA polymerase gamma . Antimicrob Agents Chemother 1989; 33: 2109-2114 .

24.

Ono K , Nakane H , Herdewijn P , Balzarini J , De Clercq E . Differential inhibitory effects of several pyrimidine 2’,3’-dideoxynucleoside 5’-triphosphates on the activities of reverse transcriptase and various cellular DNA polymerases . Mol Pharmacol 1989; 35: 578-583 .

25.

Lewis W , Simpson JF , Meyer RM . Cardiac mitochondrial DNA polymerase -gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine . Circ Res 1994; 74: 344-348 .

26.

Hao Z , Cooney DA , Hartman NR , Perno CF , Fridland A , DeVico AL , et al. Factors determining the activity of 2’,3’-dideoxynucleosides in suppressing human immunode”ciency virus in vitro . Mol Pharmacol 1988; 34: 431-435 .

27.

Sommadossi JP , Carlisle R , Zhou Z . Cellular pharmacology of 3’-azido-3’-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells . Mol Pharmacol 1989; 36: 9-14 .

28.

Simpson MV , Chin CD , Keilbaugh SA , Lin TS , Prussoff WH . Studies on the inhibition of mitochondrial repli- cation by 3’-azido-3’-deoxythymidine and other dideoxynucleoside analogs inhibit HIV-1 replication . Biochem Pharmacol 1989; 38: 1033-1036 .

29.

Chen CH , Cheng YC . Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunode”ciency virus compound 2’,3’-dideoxycytidine . J Biol Chem 1989; 264: 11934-11937 .

30.

Chen JJ , Jones ME . The cellular location of dihydroorotate dehydrogenase: relation to de novo biosynthesis of pyrimidines . Arch Biochem Biophys 1976; 176: 82-90 .

31.

Gregoire M , Morais R , Quilliam MA , Gravel D . On auxotrophy for pyrimidines of respiration de”cient chicken embryo cells . Eur J Biochem 1984; 142: 49-55 .

32.

McKay R , Druyan T , Getz GS , Rabinowitz M . Intramitochondrial localisation of delta aminolevulinic acid and ferrochelatase in rat liver . Biochem J 1969; 114: 455-461 .

33.

Grandchamp B , Phung N , Nordmann Y . The mitochondrial localisation of coproporphorinogen III oxidase . Biochem J 1978; 176: 97-102 .

34.

Civin CI , Strauss LC , Fackler MJ , Trischmann TM , Wiley JM , Loken MR . Positive stem cell selection: basic science. In Gross S , Gee A , Worthington-White D eds. Bone marrow purging and processing. New York, NY: Alan R. Liss , 1990: 387-402.

35.

Civin CI . Human monomyeloid cell membrane antigens . Exp Hematol 1990; 18: 461-467 .

36.

Civin CI , Loken MR . Cell surface antigens on human marrow cells: dissection of hematopoietic development using monoclonal antibodies and multiparameter ‘ow cytometry . Int J Cell Cloning 1987; 5: 267-288 .

37.

Loken MR , Shah VO , Dattillio KL , Civin CI . Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development . Blood 1987; 70: 1316-1324 .

38.

Marbach EP , Weil MH . Rapid enzymatic measurement of blood lactate and pyruvate. Use and signi”cance of metaphosphoric acid as a precipitant . Clin Chem 1967; 13: 314-327 .

39.

Shuster RC , Rubenstein AJ , Wallace DC . Mitochondrial DNA in anucleate human blood cells . Biochem Biophys Res Commun 1988; 155: 1360-1365 .

40.

Johnson M , Caiazzo T , Molina JM , Donahue R , Groopman J . Inhibition of bone marrow myelopoiesis and erythropoiesis in vitro by anti-retroviral nucleoside derivatives . Br J Haematol 1988; 70: 137-141 .

41.

Sommadossi JP , Carlisle R , Schinazi RF , Zhou Z . Uridine reverses the toxicity of 3’-azido-3’-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of anti- retroviral activity . Antimicrob Agents Chemother 1988; 32: 997-1001 .

42.

Weinberg RS , Chusid ED , Galperin Y , Thomson JC , Cheung T , Sacks HS . Effect of antiviral drugs and hematopoietic growth factors on in vitro erythropoiesis . Mt Sinai J Med 1998: 65; 5-13 .

43.

Lerza R , Castello G , Mela GS , Arboscello E , Cerruti A , Bogliolo G , Mencoboni M , Ballarino P , Pannacciulli I . In vitro synergistic inhibition of human bone marrow hemopoietic progenitor growth by a 3’-azido-3’-deoxythymidine, 2’,3’-dideoxycytidine combination . Exp Hematol 1997; 25: 252-255 .

44.

Faraj A , Fowler DA , Bridges EG , Sommadossi JP . Effects of 2’,3’-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis . Antimicrob Agents Chemother 1994; 38: 924-930 .

45.

Dainiak N , Worthington M , Riordan MA , Kreczko S , Goldman L . 3’-Azido-3’-deoxythymidine (AZT) inhibits proliferation in vitro of human haematopoietic progenitor cells . Br J Haematol 1988; 69: 299-304 .

46.

Walker RE , Parker RI , Kovacs JA , Masur H , Lane HC , Carleton S , et al. Anemia and erythropoiesis in patients with the acquired immunode”ciency syndrome (AIDS) and kaposi sarcoma with zidovudine . Ann Int Med 1988; 108: 372-376 .

47.

Nakajima O , Takahashi S , Harigae H , Furuyama K , Hayashi N , Sassa S , Yamamoto M . Heme de”ciency in erythroid lineage causes differentiation arrest and cytoplasmic iron overload . EMBO J 1999; 18: 6282-6289 .

48.

Scott JL , Finegold SM , Belthin GS . A controlled double blind study of the haematologic toxicity of chloramphenicol . N Engl J Med 1965; 272: 1137-1142 .

49.

Manyan DR , Arimura GK , Yunis AE . Chloramphenicol induced erythroid suppression and bone marrow ferrochelatase activity in dogs . J Lab Clin Med 1972; 79: 137-144 .

50.

Yunis AA , Smith US , Restrapo A . Reversible bone marrow suppression from chloramphenicol. A consequence of mitochondrial injury . Arch Int Med 1970; 126: 272-275 .

51.

Lewis LD , Hamzeh FM , Lietman PS . Ultrastructural changes associated with reduced mitochondrial DNA and impaired mitochondrial function in the presence of 2’ 3’-dideoxcytidine . Antimicrob Agents Chemother 1992; 36: 2061-2065 .

52.

Chen C-H , Vazquez-Padua M , Cheng YC . Effect of anti- human immunode”ciency virus nucleoside analogs on mitochondrial DNA and its implications for delayed toxicity . Mol Pharmacol 1991; 39: 625-628 .

53.

Medina DJ , Tsai C-H , Hsiung GD , Cheng YC . Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunode”ciency virus dideoxynucleosides . Antimicrob Agents Che- mother 1994; 38: 1824-1828 .

54.

Tsai T-C , Doong S-L , Johns DG , Driscoll JS , Cheng YC . Effect of anti-HIV-1 2’-B-‘uoro-2’-3’-dideoxynucleo- side analogs on the cellular content of mitochondrial DNA and on lactate production . Biochem Pharmacol 1994; 48: 1477-1481 .

55.

Pearson HA , Lobel JS , Kocoshis SA , Naiman JL , Windmiller J , Lammi AT , et al. A new syndrome of refractory sideroblastic anaemia with vacuolisation of marrow precursors and exocrine dysfunction . J Pediatr 1979; 95: 976-984 .

56.

Rotig A , Colonna M , Bonnefont JP , Blanche S , Fischer A , Saudubray JM , et al. Mitochondrial DNA deletion in Pearson's marrow/pancreas syndrome . Lancet 1989; i: 902-903 .

57.

Rotig A , Cormier V , Blanche S , Bonnefont J-P , Ledeist F , Romero N , et al. Pearson's Marrow-Pancreas Syndrome. A multisystem mitochondrial disorder in infancy . J Clin Invest 1990; 86: 1601-1608 .

58.

Sano T , Ban K , Ichiki M , Kobayashi M , Tanaka M , Ohno K , et al. Molecular and genetic analyses of two patients with Pearson's marrow-pancreas syndrome . Pediatr Res 1993; 34: 105-110 .

59.

Agarwal RP , Olivero OA . Genotoxicity and mitochondrial damage in human lymphocytic cells chronically exposed to 3’-azido-2’apos;,3’apos;-dideoxythymidine . Mutat Res 1997; 390: 223-231 .

60.

Chariot P , Monnet I , Gherardi R . Cytochrome c oxidase reaction improves histopathological assessment of zidovudine myopathy . Ann Neurol 1993; 34: 561-565 .

61.

Lewis W , Gonzalez B , Chomyn A , Papoian T . Zidovu- dine induces molecular, biochemical and ultrastructural changes in rat skeletal muscle mitochondria . J Clin Invest 1992; 89: 1354-1360 .

62.

Lamperth L , Dalakas MC , Dagani F , Anderson J , Ferrari R . Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model . Lab Invest 1991; 65: 742-751 .

63.

Dalakas MC , Illa I , Pezeshkpour GH , Laukaitis JP , Cohen B , Grif”n JL . Mitochondrial myopathy caused by long-term zidovudine therapy . N Engl J Med 1990; 322: 1098-1105 .

64.

Arnaudo E , Dalakas MC , Shanske S , Moraes CT , Dimauro S , Schon EA . Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy . Lancet 1991; 337: 508-510 .

65.

Nolan D , Hammond E , Martin A , Taylor L , Herrmann S , McKinnon E , Metcalf C , Latham B , Mallal S . Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy . AIDS 2003; 17: 1329-1338 .

66.

Lewis W , Haase CP , Raidel SM , Russ RB , Sutliff RL , Hoit BD , Samarel AM . Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice . Lab Invest 2001; 81: 1527-1536 .

67.

Koch RO , Graziadei IW , Zangerle R , Romani N , Maier H , Vogel W . Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV-1 . Wien Klin Wochenschr 2003; 115: 135-140 .

68.

Keilbaugh SA , Hobbs GA , Simpson MV . Effect of 2’,3’-dideoxycytidine on oxidative phosphorylation in the PC12 cell, a neuronal model . Biochem Pharmacol 1997; 53: 1485-1492 .

69.

Barile M , Valenti D , Passarella S , Quagliariello E . 3’- Azido-3’-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator . Biochem Pharmacol 1997; 53: 913-920 .